AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

NASDAQ:AVDL • IE00BDGMC594

21.64 USD
+0.01 (+0.05%)
At close: Feb 11, 2026
21.65 USD
+0.01 (+0.05%)
After Hours: 2/11/2026, 8:07:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall AVDL gets a fundamental rating of 5 out of 10. We evaluated AVDL against 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AVDL as it has an excellent financial health rating, but there are worries on the profitability. AVDL is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year AVDL has reported negative net income.
  • AVDL had a positive operating cash flow in the past year.
  • In the past 5 years AVDL reported 4 times negative net income.
  • In the past 5 years AVDL always reported negative operating cash flow.
AVDL Yearly Net Income VS EBIT VS OCF VS FCFAVDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

  • With a decent Return On Assets value of -0.14%, AVDL is doing good in the industry, outperforming 78.01% of the companies in the same industry.
  • The Return On Equity of AVDL (-0.28%) is better than 80.10% of its industry peers.
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROIC N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVDL Yearly ROA, ROE, ROICAVDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • AVDL has a better Gross Margin (91.09%) than 92.67% of its industry peers.
  • In the last couple of years the Gross Margin of AVDL has grown nicely.
  • The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
AVDL Yearly Profit, Operating, Gross MarginsAVDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AVDL has been increased compared to 1 year ago.
  • AVDL has more shares outstanding than it did 5 years ago.
  • AVDL has a worse debt/assets ratio than last year.
AVDL Yearly Shares OutstandingAVDL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVDL Yearly Total Debt VS Total AssetsAVDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 7.90 indicates that AVDL is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of AVDL (7.90) is better than 82.72% of its industry peers.
  • The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
  • AVDL has a better Debt to FCF ratio (1.80) than 95.29% of its industry peers.
  • A Debt/Equity ratio of 0.35 indicates that AVDL is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.35, AVDL is in line with its industry, outperforming 40.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Altman-Z 7.9
ROIC/WACCN/A
WACC7.87%
AVDL Yearly LT Debt VS Equity VS FCFAVDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 2.76 indicates that AVDL has no problem at all paying its short term obligations.
  • AVDL has a Current ratio (2.76) which is comparable to the rest of the industry.
  • A Quick Ratio of 2.37 indicates that AVDL has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.37, AVDL is in line with its industry, outperforming 48.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.37
AVDL Yearly Current Assets VS Current LiabilitesAVDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 100.00% over the past year.
  • AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.88%.
  • AVDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.35% yearly.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%

3.2 Future

  • The Earnings Per Share is expected to grow by 39.72% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, AVDL will show a very strong growth in Revenue. The Revenue will grow by 24.44% on average per year.
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
AVDL Yearly Revenue VS EstimatesAVDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AVDL Yearly EPS VS EstimatesAVDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Forward Earnings ratio of 26.23, the valuation of AVDL can be described as expensive.
  • Based on the Price/Forward Earnings ratio, AVDL is valued a bit cheaper than 73.82% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, AVDL is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 26.23
AVDL Price Earnings VS Forward Price EarningsAVDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • AVDL's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. AVDL is cheaper than 76.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 101.28
EV/EBITDA N/A
AVDL Per share dataAVDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AVDL's earnings are expected to grow with 64.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.39%
EPS Next 3Y64.19%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AVDL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (2/11/2026, 8:07:16 PM)

After market: 21.65 +0.01 (+0.05%)

21.64

+0.01 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04
Earnings (Next)03-09
Inst Owners95.18%
Inst Owner Change1.67%
Ins Owners1.06%
Ins Owner Change0%
Market Cap1.96B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target21.48 (-0.74%)
Short Float %4.02%
Short Ratio2.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)8.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.63%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.53%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 26.23
P/S 7.89
P/FCF 101.28
P/OCF 56.74
P/B 19.96
P/tB 24.08
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.83
Fwd EY3.81%
FCF(TTM)0.21
FCFY0.99%
OCF(TTM)0.38
OCFY1.76%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.14%
ROE -0.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.09%
FCFM 7.79%
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.8
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.37
Altman-Z 7.9
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y39.72%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y24.44%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.2%
EBIT Next 3Y69.86%
EBIT Next 5Y44.48%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A

AVADEL PHARMACEUTICALS / AVDL FAQ

Can you provide the ChartMill fundamental rating for AVADEL PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 5 / 10 to AVDL.


What is the valuation status of AVADEL PHARMACEUTICALS (AVDL) stock?

ChartMill assigns a valuation rating of 4 / 10 to AVADEL PHARMACEUTICALS (AVDL). This can be considered as Fairly Valued.


How profitable is AVADEL PHARMACEUTICALS (AVDL) stock?

AVADEL PHARMACEUTICALS (AVDL) has a profitability rating of 3 / 10.


What is the financial health of AVADEL PHARMACEUTICALS (AVDL) stock?

The financial health rating of AVADEL PHARMACEUTICALS (AVDL) is 7 / 10.